Providing Cancer Care Closer to Home for Patients With Multiple Myeloma

NCT05971056 | Terminated

• 1 other identifier: 202306162
• Study Type: interventional
• Target: 3
• Locations: 1 country
• Sites: 1

Brief Summary

There is very limited data on the utilization of National Cancer Institute Comprehensive Cancer Center (NCI-CCC) satellite sites in general. Of what is available, most is in regards to providing chemotherapy at facilities closer to patients' home. These "satellite chemotherapy infusion centers", typically community-based treatment locations at community hospitals/facilities, freestanding clinics, or mobile units, are reported to be well liked by patients who utilize their services and reduce their travel times and expenses. In these studies patients still remained in the care of their current provider and site and are required to travel to the site for clinical visits and other appointments. It is currently unknown if patients are willing to transfer their care to a different provider to alleviate travel burden. In addition, although increased travel burden has been lower quality of life in cross-sectional studies, no data exists suggesting that these reducing travel burden can improve these outcomes intra-patient, to the knowledge of the investigators. The patient roles of the multiple myeloma clinical providers at the Siteman primary location have grown in recent years. The providers have determined a need to refer some patients to the satellite sites to relieve congestion at the site while also hopefully improving the clinical experience for those patients. This study is a natural experiment of this process.

Conditions

Multiple Myeloma

Keywords

access to care; travel burden; financial toxicity; patient satisfaction

Outcome Measures

Primary Outcomes (1)

• Proportion of eligible participants who successfully transfer to the provider at a satellite location

  At time of transfer decision (day 1)

Secondary Outcomes (5)

• Types of candidacy that providers use for transfer of care to satellite sites

  At time of transfer decision (day 1)

• Treatment burden of participants as measured by the Modified Treatment Burden Questionnaire

  Through completion of follow-up (estimated to be 6 months)

• Satisfaction of with participant-provider interactions as measured by the Questionnaire on the Quality of Physician-Patient Interaction

  Through completion of follow-up (estimated to be 6 months)

• Financial toxicity of participants as measured by the Comprehensive Score for Financial Toxicity

  Through completion of follow-up (estimated to be 6 months)

• Participant rationales for opting to transfer to a satellite site or maintain care at their usual site.

  Through completion of follow-up (estimated to be 6 months)

Study Arms (2)

Care transition

EXPERIMENTAL

-At baseline, the participant and the provider will make a decision on if the participant will transfer care to a satellite location.

Other: Care transition

No care transition

ACTIVE COMPARATOR

-At baseline, the participant and the provider will make a decision on if the participant will transfer care to a satellite location.

Other: No care transition

Interventions

Care transition OTHER

Cancer care is transitioned to a satellite site.

Care transition

No care transition OTHER

Cancer care is not transitioned to a satellite site.

No care transition

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

Eligibility Criteria * At least 18 years old * Diagnosed with multiple myeloma * Receiving care from a provider within the Division of Oncology at the primary Siteman Cancer Center site * Resides within the catchment area of a Siteman Cancer Center satellite site * Able to read, speak, and understand English * Willing to provide informed consent

Contact the study team to discuss eligibility requirements. They can help determine if this study is right for you.

Sponsors & Collaborators

• Washington University School of Medicine: lead

Study Sites (1)

Washington University School of Medicine

St Louis, Missouri, 63110, United States

Location

Related Links

• Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine

MeSH Terms

Conditions

Multiple Myeloma; Financial Stress; Patient Satisfaction

Interventions

Patient Transfer

Condition Hierarchy (Ancestors)

Neoplasms, Plasma Cell; Neoplasms by Histologic Type; Neoplasms; Hemostatic Disorders; Vascular Diseases; Cardiovascular Diseases; Paraproteinemias; Blood Protein Disorders; Hematologic Diseases; Hemic and Lymphatic Diseases; Hemorrhagic Disorders; Lymphoproliferative Disorders; Immunoproliferative Disorders; Immune System Diseases; Stress, Psychological; Behavioral Symptoms; Behavior; Treatment Adherence and Compliance; Health Behavior

Intervention Hierarchy (Ancestors)

Continuity of Patient Care; Patient Care; Therapeutics; Hospitalization; Health Services; Health Care Facilities Workforce and Services; Primary Health Care; Comprehensive Health Care; Patient Care Management; Health Services Administration

Study Officials

• Mark Fiala, Ph.D., MSW

  Washington University School of Medicine

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: HEALTH SERVICES RESEARCH
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 20, 2023
• First Posted: August 2, 2023
• Study Start: September 8, 2023
• Primary Completion: March 22, 2024
• Study Completion: March 22, 2024
• Last Updated: October 3, 2024

Record last verified: 2024-10

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)